Ignite Creation Date:
2024-05-06 @ 12:26 AM
Last Modification Date:
2024-10-26 @ 10:49 AM
Study NCT ID:
NCT01570439
Status:
UNKNOWN
Last Update Posted:
2013-12-11
First Post:
2012-04-02
Brief Title:
To Identify HLA-A1101-restricted Peptide Epitopes Derived From Novel Oncoantigens URLC10 KIF20A and CDCA1 Applicable for Cancer Vaccine in Singapore
Sponsor:
National University Hospital Singapore
Organization:
National University Hospital Singapore
Study Overview
Official Title:
None
Status:
UNKNOWN
Status Verified Date:
2013-12
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Aim To identify HLA-A1101-restricted peptide epitopes derived from novel Oncoantigens URLC10 KIF20A and CDCA1 applicable for Cancer Vaccine in Singapore
Methods The panel of candidate peptides are synthesized and tested for their ability to induce peptide-specific CTL responses in order to screen the peptide epitopes applicable for the cancer vaccination Briefly peripheral blood lymphocytes PBLs derived from HLA-A1101 healthy donors are taken and cultured in the presence of the each candidate peptide with recombinant IL-2 for 2 weeks and then re-stimulated with dendritic cell pulsed with the peptide following another 2 week culture Thereafter CD8 T lymphocytes were negatively selected with CD4-magnetic beads from cultured lymphocytes and tested for their peptide specificity employing enzyme-linked immunospot ELISPOT assay These conditions are completely performed in in-vitro system Importance in medicine If one could identify the peptide epitopes from novel Oncoantigens it is applicable for clinical trials of cancer vaccination
Benefits Risks There is no risk except for the matter of venipuncture in each individuals
The ideal target molecules for cancer vaccination are thought to be selectively expressed in tumor cells but not in the normal cells with high frequent and homogenous expression within tumor We have proved that novel Oncoantigens URLC10 KIF20A and CDCA1 have these characters as ideal target molecules for the cancer vaccination and are highly expressed in a variety of tumor type such as gastric lung and pancreas cancer Since HLA-A1101 haplotype is most frequent in Singaporean it is essential to indentify the HLA-A1101-restriced peptides derived from these Oncoantigens to develop cancer vaccination
Methods The panel of candidate peptides are synthesized and tested for their ability to induce peptide-specific CTL responses in order to screen the peptide epitopes applicable for the cancer vaccination Briefly peripheral blood lymphocytes PBLs derived from HLA-A1101 healthy donors are taken and cultured in the presence of the each candidate peptide with recombinant IL-2 for 2 weeks and then re-stimulated with dendritic cell pulsed with the peptide following another 2 week culture Thereafter CD8 T lymphocytes were negatively selected with CD4-magnetic beads from cultured lymphocytes and tested for their peptide specificity employing enzyme-linked immunospot ELISPOT assay These conditions are completely performed in in-vitro system Importance in medicine If one could identify the peptide epitopes from novel Oncoantigens it is applicable for clinical trials of cancer vaccination
Benefits Risks There is no risk except for the matter of venipuncture in each individuals
The ideal target molecules for cancer vaccination are thought to be selectively expressed in tumor cells but not in the normal cells with high frequent and homogenous expression within tumor We have proved that novel Oncoantigens URLC10 KIF20A and CDCA1 have these characters as ideal target molecules for the cancer vaccination and are highly expressed in a variety of tumor type such as gastric lung and pancreas cancer Since HLA-A1101 haplotype is most frequent in Singaporean it is essential to indentify the HLA-A1101-restriced peptides derived from these Oncoantigens to develop cancer vaccination
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None